Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Topotecan for Primary CNS Lymphoma
NCT00109798Phase 2Withdrawn
- Sponsor
- Houston Methodist Research Institute
- Start
- Mar 2005
- Primary completion
- Jul 2006
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
A Phase 2 trial of temozolomide, topotecan liposome in primary central nervous system lymphoma (PCNSL), sponsored by Houston Methodist Research Institute. Planned start Mar 2005; status: withdrawn.
02
Drugs
temozolomidetopotecan liposome
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00109798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00109798.